Invex Therapeutics Ltd (ASX:IXC)

Market Cap	6.99M
Revenue (ttm)	1.21M
Net Income (ttm)	114.36K
Shares Out	75.15M
EPS (ttm)	0.00
PE Ratio	61.55
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,622
Average Volume	39,435
Open	0.0950
Previous Close	0.0930
Day's Range	0.0940 - 0.0950
52-Week Range	0.0590 - 0.1000
Beta	0.01
RSI	72.00
Earnings Date	May 7, 2025

About Invex Therapeutics

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IXC

Financial Performance

In 2024, Invex Therapeutics's revenue was 1.21 million, an increase of 164.06% compared to the previous year's 459,085. Losses were -1.64 million, -78.81% less than in 2023.